CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
SeaBeLife is a biotechnology company focused on developing innovative drugs for severe organ pathologies, specifically targeting Acute Liver Failure and retinal diseases. Their unique dual-targeted approach aims to prevent cell death and restore organ function, with promising results from preclinical models.
I am the CEO and Cofounder of SeaBeLife, a French biotechnology company developing First-In-Class drugs to treat severe pathologies affecting our vital organs for which there are no effective treatments.
We develop an innovative therapeutic approach protected by 4 patents and with a lead program to treat Acute Liver Failure and a second program to preserve sight and halting vision loss associated with a range of retinal disease by preventing the death of key retinal cells.
We are developing a fi…
SEABELIFE SAS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
